|
Market Closed -
Nasdaq Stockholm
12:00:00 2026-08-19 EDT
|
5-day change | 1st Jan Change | ||
| 21.45 SEK | +7.25% |
|
+11.14% | -5.09% |
| 08-19 | Synact Pharma signs term sheet with Hipolabor on resomelagon in Brazil | FW |
| 08-06 | SynAct Pharma Secures Appellate Board Backing in US Patent Application | MT |
Projected Income Statement: SynAct Pharma AB
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 138.8 | 21.15 | 76.3 |
| Change | - | - | - | - | - | - | -84.76% | 260.76% |
| EBITDA 1 | - | - | -224.5 | -89.98 | -116.5 | 48.28 | -29.82 | 26.9 |
| Change | - | - | - | 59.92% | -29.52% | 141.42% | -161.78% | 190.19% |
| EBIT 1 | - | - | -224.5 | -89.98 | -116.5 | 48.02 | -29.96 | 26.9 |
| Change | - | - | - | 59.92% | -29.52% | 141.2% | -162.39% | 189.8% |
| Interest Paid 1 | - | - | - | - | -2.451 | -1.64 | - | - |
| Earnings before Tax (EBT) 1 | - | - | -224.3 | -90.82 | -119 | 48.1 | -28.95 | 26.9 |
| Change | - | - | - | 59.5% | -31.01% | 140.42% | -160.19% | 192.92% |
| Net income 1 | -69.3 | -99.2 | -215.8 | -82.4 | -110.8 | 52.18 | -26.04 | 26.9 |
| Change | - | -43.14% | -117.54% | 61.82% | -34.5% | 147.08% | -149.92% | 203.28% |
| Announcement Date | 2/11/22 | 2/17/23 | 2/23/24 | 2/18/25 | 2/18/26 | - | - | - |
1SEK in Million
Estimates
Forecast Balance Sheet: SynAct Pharma AB
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | -46.8 | -53.4 | -17.5 | 24.9 | - |
| Change | - | - | - | - | -14.1% | 67.23% | 242.29% | - |
| Announcement Date | 2/11/22 | 2/17/23 | 2/23/24 | 2/18/25 | 2/18/26 | - | - | - |
1SEK in Million
Estimates
Cash Flow Forecast: SynAct Pharma AB
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| CAPEX 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Free Cash Flow (FCF) 1 | -12.13 | -43.37 | -84.11 | 25.55 | -62.5 | -62.83 |
| Change | - | -257.55% | -93.95% | 130.38% | -344.61% | -0.54% |
| Announcement Date | 4/19/21 | 4/29/22 | 4/13/23 | 3/26/24 | 4/10/25 | 4/15/26 |
1SEK in Million
Estimates
Forecast Financial Ratios: SynAct Pharma AB
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
| EBITDA Margin (%) | - | - | - | - | - | - | 34.79% | -141.02% | 35.26% |
| EBIT Margin (%) | - | - | - | - | - | - | 34.61% | -141.63% | 35.26% |
| EBT Margin (%) | - | - | - | - | - | - | 34.67% | -136.88% | 35.26% |
| Net margin (%) | - | - | - | - | - | - | 37.6% | -123.14% | 35.26% |
| FCF margin (%) | - | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | 46.42% | 108.25% | - | - | - | - |
Profitability | |||||||||
| ROA | -82.32% | -159.89% | -70.16% | -46.86% | -22.48% | -29.6% | - | - | - |
| ROE | -189.27% | -377.3% | -134.62% | -142.59% | -42.22% | -57.65% | - | - | - |
Financial Health | |||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | -0.83x | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - | - |
Capital Intensity | |||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - | - |
Items per share | |||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - | - |
| EPS 1 | - | -2.68 | -3.6 | -6.64 | -2.08 | -2.17 | -1.49 | -0.76 | - |
| Change | - | - | -34.33% | -84.44% | 68.67% | -4.33% | 31.34% | 48.99% | - |
| Nbr of stocks (in thousands) | - | 26,006 | 29,648 | 35,571 | 46,487 | 53,330 | 55,998 | 55,998 | - |
| Announcement Date | - | 2/11/22 | 2/17/23 | 2/23/24 | 2/18/25 | 2/18/26 | - | - | - |
1SEK
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -14.4x | -28.2x |
| PBR | - | - |
| EV / Sales | 8.53x | 58x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYNACT Stock
- Financials SynAct Pharma AB
Select your edition
All financial news and data tailored to specific country editions
